Angiotensin-converting enzyme inhibitors (ACEis) are associated with symptomatic improvement, reduced progression of HF, decreased hospitalization, and improved survival in adults with HF.26, 27, 28, 29 Pediatric trials of this class of mediation have been small and seem to indicate a differential benefit based on the underlying etiology of HF. This evidence concerns the gene ACE and hydrops fetalis.